A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (Build Uc)
Phase of Trial: Phase II
Latest Information Update: 12 Mar 2018
At a glance
- Drugs F8 IL10 (Primary) ; Infliximab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Pfizer
- 12 Jan 2018 Planned number of patients changed from 68 to 98.
- 12 Jan 2018 Planned End Date changed from 1 Feb 2020 to 26 Feb 2020.
- 12 Jan 2018 Planned primary completion date changed from 1 Feb 2020 to 26 Feb 2020.